金吾财讯 | 据外媒报道，艾伯维（ABBV）周二宣布，Rinvoq获欧盟批准，用于治疗对一种或多种改善病情抗风湿药（DMARD）应答不足或不耐受的2岁及以上活动性多关节型幼年特发性关节炎患者。
艾伯维表示，Rinvoq可单药使用，也可与甲氨蝶呤联合用药。本次获批依据开放标签Ⅰ期SELECT-YOUTH研究以及成人类风湿关节炎的相关临床数据，同时该药物全新口服溶液剂型也获批用于pJIA患者。此外，Rinvoq在欧盟已获批11项针对各类免疫介导性炎症性疾病的适应症。
金吾财讯 | 据外媒报道，艾伯维（ABBV）周二宣布，Rinvoq获欧盟批准，用于治疗对一种或多种改善病情抗风湿药（DMARD）应答不足或不耐受的2岁及以上活动性多关节型幼年特发性关节炎患者。
艾伯维表示，Rinvoq可单药使用，也可与甲氨蝶呤联合用药。本次获批依据开放标签Ⅰ期SELECT-YOUTH研究以及成人类风湿关节炎的相关临床数据，同时该药物全新口服溶液剂型也获批用于pJIA患者。此外，Rinvoq在欧盟已获批11项针对各类免疫介导性炎症性疾病的适应症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.